On February 27, 2024 Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, reported that CEO Caroline Loew, Ph.D. will present at the TD Cowen 44th Annual Health Care Conference on March 5th at 10:30am ET (Press release, Mural Oncology, FEB 27, 2024, View Source [SID1234640522]). A live webcast of the presentation will be available at ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!